MOTS-c Australia: Human Evidence, Exercise Studies and WADA Status

Overview: Evidence-led MOTS-c guide covering human exercise and biomarker studies, limits of animal research, Australian regulatory context and 2026 WADA status.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide studied in cellular stress, metabolism and exercise biology. Human research has measured naturally occurring MOTS-c and associated mitochondrial variants, but this is not the same as demonstrating that administered MOTS-c improves weight, longevity or exercise performance in people.

What is MOTS-c?

MOTS-c—short for “mitochondrial open reading frame of the 12S rRNA type-c”—is encoded within mitochondrial DNA rather than the nuclear genome. That feature makes it part of the emerging field of mitochondrial-derived peptides: short signals investigated for communication between mitochondria, the cytoplasm and the nucleus.

The foundational 2015 work identified metabolic effects in cultured cells and mice, including changes in skeletal-muscle glucose handling and protection against diet-induced metabolic dysfunction. These experiments established a research programme. They did not establish a medicine, a human dose or a clinical benefit.

The four evidence categories should not be mixed

What human studies actually show

Are there human MOTS-c trials in 2026?

A registered intervention is different from a published benefit. ClinicalTrials.gov lists a sponsor-submitted phase 2 MOTS-c study, but its record has no posted results as checked on 27 October 2026. Human exercise measurements and the older CB4211 trial answer different questions and should not be pooled as if they tested the same treatment.

The planned 120 participants are not 120 reported treatment outcomes. The MOTS-MET record was last updated on 1 April 2026. Its current registry label is not independent verification that recruitment is proceeding as described, nor a regulator’s endorsement. A proposed insulin-sensitivity endpoint is not an observed weight-loss, longevity or exercise-performance benefit.

The CB4211 registry’s completion date is 19 April 2021. Its 88-person total should not be described as 88 people in the fatty-liver subgroup. “No results posted” refers to the registry’s structured results section, not a claim that the developer never issued an announcement.

For both intervention records, look next for actual participant flow, prespecified outcome estimates, uncertainty and adverse-event denominators. Use our clinical-trial registry reading guide to separate a study plan from a result. These are selected records for interpretation, not a systematic review or a recruitment recommendation.

Targeted source check: 27 October 2026, using both current ClinicalTrials.gov records, the 2021 primary paper and the developer’s dated identity statement. Earlier whole-profile review and regulatory checks retain their original dates.

Exercise-response measurements

A 2021 study reported that exercise increased endogenous MOTS-c in skeletal muscle and circulation in a small human component, alongside extensive cell and mouse work. The important distinction is that researchers measured the body’s own response to exercise; participants were not randomised to receive MOTS-c as a therapy. Calling that finding proof of an “exercise-mimetic” treatment reverses the direction of the experiment.

A separate exercise study in women treated for breast cancer examined how aerobic and resistance training related to circulating MOTS-c. This contributes to biomarker research, but it does not prove that an external MOTS-c product reproduces training adaptations.

Metabolic regulation studies

Human laboratory work has reported that lipid and insulin conditions can alter circulating MOTS-c. That supports the idea that MOTS-c participates in metabolic signalling. It does not show that increasing MOTS-c externally treats diabetes, obesity or age-related decline.

Mitochondrial genetic variation

Researchers have also studied a mitochondrial DNA variant that changes the MOTS-c sequence and is associated with metabolic traits in some populations. Genetic association can strengthen biological plausibility, but it remains vulnerable to population structure, confounding and limited transferability across ancestries. It is not a substitute for a controlled therapeutic trial.

What does the 2026 mitochondrial study add?

A 2026 skeletal-muscle study reported that administered MOTS-c improved mitochondrial bioenergetic measures in transgenic mice through PGC-1α- and AMPK-dependent mechanisms. Its human component measured endogenous MOTS-c around one-legged exercise; it did not test MOTS-c administration as a human therapy.

The paper supports a mechanism in the experimental models and contributes human exercise measurements. It does not establish clinical weight loss, exercise replacement, longevity benefit or the safety of an administered product in people. Paper checked: 20 October 2026.

Why the animal findings receive attention

Mouse studies have reported effects on insulin sensitivity, physical performance, metabolic stress and late-life health measures. In the 2021 exercise paper, intermittent administration improved physical capacity in mice of different ages. More recent preclinical research continues to investigate skeletal-muscle mitochondrial bioenergetics.

These findings are useful for generating hypotheses and identifying measurable pathways. Translation still requires characterised material, pharmacokinetics, toxicology, dose-ranging work, blinded controls, clinically meaningful endpoints and adequate follow-up in humans.

Mechanism: plausible does not mean clinically proven

Experimental work links MOTS-c to cellular energy sensing, including AMPK-related pathways, folate and purine metabolism, nuclear translocation under stress and regulation of stress-response genes. Mechanistic coherence can explain why an intervention might work. It cannot tell readers how large an effect would be in people, who might benefit, how long an effect lasts or what harms emerge with repeated exposure.

MOTS-c in Australia

Source check: 20 October 2026. A text search of the October 2026 Poisons Standard did not find an individual MOTS-c entry. That narrow result does not exclude broader entries or other controls and does not establish lawful supply or approval.

Check the particular finished product and sponsor in the ARTG. The TGA’s peptide guidance explains why a research label cannot substitute for product assessment. Our Australian regulatory-pathways guide separates registration, unapproved-goods pathways and clinical trials.

WADA status in 2026

The 2026 WADA Prohibited List names MOTS-c under S4.4.1 (AMPK activators), prohibited at all times. This list is in force for 2026. Anti-doping classification is separate from Australian medicine approval and scheduling. Official entry checked: 20 October 2026.

For context, read Peptides and Sport: the 2026 WADA Prohibited List explained.

Quality claims do not fill the clinical-evidence gap

An HPLC chromatogram may describe chromatographic behaviour in the submitted sample. Peak-area percentage does not by itself prove identity, dose accuracy, sterility, endotoxin control, absence of every impurity or stability over time. Mass spectrometry, reference standards, method suitability, representative sampling and chain of custody answer different questions.

See how to read an HPLC chromatogram without confusing peak area with purity and our field-by-field certificate-of-analysis guide.

Claims the current evidence does not establish

• That administered MOTS-c produces weight loss in humans.
• That it improves human lifespan or reverses biological ageing.
• That it safely reproduces the benefits of exercise.
• That a marketed vial matches material used in a published experiment.
• That a high HPLC percentage demonstrates clinical-grade quality.
• That WADA prohibition implies therapeutic approval—or vice versa.

Research questions that would materially change confidence

• Registered, randomised human trials with prespecified endpoints.
• Transparent pharmacokinetic and dose-ranging data.
• Repeated-exposure toxicology and longer follow-up.
• Validated assays capable of distinguishing endogenous from administered material.
• Replication by independent groups using characterised material.
• Publication of null results and adverse-event data, not only mechanistic signals.

Primary sources and official references

• Lee et al. (2015): foundational cell and mouse metabolic study
• Reynolds et al. (2021): exercise-induced MOTS-c, human measurements and mouse performance experiments
• Dieli-Conwright et al. (2021): aerobic and resistance exercise study
• Ramanjaneya et al. (2019): lipid and insulin regulation of circulating MOTS-c
• Zempo et al. (2021): mitochondrial variant and metabolic association research
• WADA 2026 Prohibited List
• Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026
• TGA: searching the ARTG

Editorial scope: evidence interpretation and regulatory context only. This page does not provide dosing, administration, sourcing or medical advice.